Valuable Targets

Targeting the Amylin Receptor for Obesity Weight Reduction

7 March 2024
2 min read

Islet Amyloid Polypeptide (IAPP), also known as amylin, is a peptide hormone composed of 37 amino acids, secreted by the pancreatic beta-cells.

图示

描述已自动生成

Amylin acts as an appetite suppressant. It inhibits gastrointestinal motility and delays gastric emptying after meals, thereby reducing appetite. The metabolic regulatory functions of amylin are mediated by the Amylin receptors (AMYRs), making these receptors an important pharmaceutical target in the treatment of diabetes and obesity.

图示

描述已自动生成

Taking Pramlintide as an example, it is a synthetic analog of human insulin composed of 31 amino acids. Developed by AstraZeneca, it was approved for market in 2005 for the treatment of type 1 diabetes. Due to the highly amyloidogenic nature of endogenous human insulin, researchers took inspiration from the proline residues in rat insulin, which are highly homologous but not amyloidogenic (known to disrupt the secondary structure), and incorporated them into the human insulin sequence to develop Pramlintide.

Insulin receptors are a class of special protein heterodimers, composed of a calcitonin receptor (CTR) combined with three homologous receptor activity-modifying proteins (RAMP 1,2,3), forming three subtypes (AMY1, AMY2, AMY3).

图示

描述已自动生成

The cagrilintide developed by Novo Nordisk is a long-acting insulin analog. Studies have shown that cagrilintide can act on both the calcitonin receptor and three different subtypes of insulin receptors. Additionally, clinical results indicate that cagrilintide possesses effective weight-reducing properties.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序

描述已自动生成

Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
Latest Hotspot
4 min read
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
7 March 2024
Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.
Read →
Synapse Simplified: How to Find Clotrimazole Information
Drug Insights
2 min read
Synapse Simplified: How to Find Clotrimazole Information
7 March 2024
Clotrimazole, a diminutive molecule of pharmacological relevance, exerts its influence as an astoundingly powerful CYP51A1 inhibitor.
Read →
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
Latest Hotspot
3 min read
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
7 March 2024
Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.
Read →
AbbVie Explores New Target ChemR23 for the Treatment of Chronic Inflammation
AbbVie Explores New Target ChemR23 for the Treatment of Chronic Inflammation
7 March 2024
AbbVie, a US-based pharma company, partnered with French firm OSE Immunotherapeutics on Feb 28 to co-develop OSE-230, a new monoclonal antibody for chronic inflammation.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.